Tang, M. W., Rhee, S. Y., Bertagnolio, S., Ford, N., Holmes, S., Sigaloff, K. C., . . . Shafer, R. W. (2018). Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine.
Chicago Style CitationTang, Michele W., et al. Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated With First-line Stavudine-containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. 2018.
MLA引文Tang, Michele W., et al. Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated With First-line Stavudine-containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. 2018.